



ASX Announcement

7 November 2017

UOW and Creso Pharma collaborate on medicinal cannabis research - Industry Partnership to further understanding of medicinal cannabis

Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) is pleased to advise that it has entered into a research collaboration with The University of Wollongong (UOW) that will support further understanding of the effect of cannabis-based products on the human central nervous system.

Under the collaboration, Creso will leverage UOW’s scientific expertise for validation and optimisation of its drug delivery systems and clinical evidence generation.

Creso is a global leader in cannabidiol innovation and develops cannabis and hemp-derived therapeutic grade nutraceuticals and medicinal cannabis products with wide patient reach for human and animal health.

Dr Katrina Green, from UOW’s School of Medicine, will lead the studies, with an emphasis on investigating how CBD, a non-intoxicating component of cannabis, influences learning, memory and attention.

Evidence from research around the world, including recent studies by Dr Green, have indicated promising results for the use of CBD in offering potential solutions for symptoms of a wide variety of conditions including schizophrenia that are not addressed by current treatments.

“The partnership with industry is important because it allows us to use commercial drug delivery systems in a controlled laboratory environment to delve into the potential, but also the unknowns, of the cannabis plant and its interaction with the central nervous system,” Dr Green said.

“Having an industry partner also creates a bench-to-bedside pathway that allows us to take fundamental research toward realisation of translational medicine.”

Creso Pharma Chief Operating Officer David Russell said: “We’re delighted to be collaborating with The University of Wollongong. Medicinal cannabis is under-researched and this collaboration will help provide the clinical evidence needed to develop safe, pharma-grade products for use in therapeutic treatments.

“This aligns with one of Creso’s aims of bringing pharmaceutical expertise and rigour to the world of medicinal cannabis. Being able to draw on the expertise from the UOW School of Medicine will be invaluable in helping to understand further the benefits and potential of medicinal cannabis.”

The partnership with Creso is further evidence of UOW’s growing expertise in understanding the effects of medicinal cannabis.

The National Health and Medical Research Council (NHMRC) recently announced funding of \$2.5 million to establish the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), led by the University of Newcastle and University of Wollongong. The world-first centre, of which Dr Green is an associated investigator, involves researchers and clinicians from at least 10 other Australian universities and other research institutions.



ACRE will undertake medical cannabinoid research, translate data into policy, and link health outcomes from people currently accessing local and imported products to guide plant growing and product formulation into appropriate medicines.

Professor Judy Raper, Deputy Vice-Chancellor (Research and Innovation) welcomed the collaboration as further evidence of UOW's research strengths.

"The collaboration is expected to be the first of several potential industry connections with growing interest in the field of medicinal cannabis and the need for a rigorous scientific evidence underpinning its safe and appropriate use in therapeutic treatment."

-ENDS-

Investor Enquiries:

Gabriella Hold
M: 0411 364 382
E: gabriella.hold@mcpartners.com.au

Media Enquiries:

Elise Hughan
M: 0458 855 500
E: elise.hughan@mcpartners.com.au

Corporate Queries:

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney, NSW 2000
E: info@everblucapital.com
P: +61 2 8249 0000

About Creso Pharma

Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medicinal cannabis and strives for the highest quality in its products. It is the leader in medicinal cannabis and cannabidiol (CBD) innovation and develops cannabis- and hemp-derived therapeutic-grade nutraceuticals and medicinal cannabis products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.